CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 237 filers reported holding CLOVIS ONCOLOGY INC in Q1 2017. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $5,280,000 | +22.8% | 118,871 | -0.3% | 0.01% | +20.0% |
| Q3 2016 | $4,300,000 | +166.9% | 119,281 | +1.6% | 0.01% | +150.0% |
| Q2 2016 | $1,611,000 | -11.7% | 117,450 | +23.6% | 0.00% | 0.0% |
| Q1 2016 | $1,824,000 | -44.2% | 95,001 | +1.7% | 0.00% | -50.0% |
| Q4 2015 | $3,270,000 | -66.8% | 93,422 | -12.8% | 0.00% | -69.2% |
| Q3 2015 | $9,847,000 | +14.3% | 107,076 | +9.2% | 0.01% | +18.2% |
| Q2 2015 | $8,618,000 | +43.1% | 98,067 | +20.9% | 0.01% | +37.5% |
| Q1 2015 | $6,021,000 | +25.0% | 81,119 | -5.7% | 0.01% | +33.3% |
| Q4 2014 | $4,815,000 | +22.8% | 85,989 | -0.5% | 0.01% | +20.0% |
| Q3 2014 | $3,921,000 | +40.4% | 86,451 | +28.2% | 0.01% | +25.0% |
| Q2 2014 | $2,792,000 | -18.6% | 67,419 | +36.1% | 0.00% | -20.0% |
| Q1 2014 | $3,430,000 | +15.8% | 49,523 | +0.7% | 0.01% | +25.0% |
| Q4 2013 | $2,963,000 | +8.6% | 49,166 | +9.6% | 0.00% | -20.0% |
| Q3 2013 | $2,728,000 | +6.8% | 44,874 | +17.7% | 0.01% | 0.0% |
| Q2 2013 | $2,555,000 | – | 38,139 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |